MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin-like growth factor 1 (IGF1)/IGF2, HGF/MET and HER2/HER3 have been reported to activate the PI3K/AKT and RAS/RAF/MEK/ERK axis independently of EGFR [172,173].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“The proto-oncogene MET, which enforces hepatocyte growth factor receptor (HGFR, also known as MET tyrosine kinase receptor), shares several downstream pathways with EGFR, including RAS/RAF/MAPK and PI3K/AKT signaling pathways [173,183].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“MET activation, by either gene amplification or ligand stimulation, accounts for 5–10% of lung cancer resistance to EGFR TKIs [12,14].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [14]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23]. In our cohort, it was identified in T790M-preserved (5/19) and T790M-loss (1/21) cases, and the second most common resistance mechanism after EGFR tertiary mutations (5/42, 14%).”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Self-citationEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Research works printed but not linked: 2
- J. G. Christensen et al., Cancer Res.63, 7345 (2003).
- F. M. Yakes et al., Cancer Res.62, 4132 (2002).
Cited by
Items 701–800 of 1,038
Treatment of kidney cancer: Insights Provided by the VHL Tumor‐Suppressor Protein
Kaelin, W. G. (2009) · Cancer · doi:10.1002/cncr.24232 · Cited by 129
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Fiszman, G. L., & Jasnis, M. A. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/352182 · Cited by 131
Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer
Byers, L. A., Sen, B., Saigal, B., Diao, L., Wang, J., Nanjundan, M., Cascone, T., Mills, G. B., Heymach, J. V., & Johnson, F. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0767 · Cited by 117
Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
Hirsch, F. R., Janne, P. A., Eberhardt, W., Cappuzzo, F., Thatcher, N., Pirker, R., Choy, H., Kim, E. S., Paz-Ares, L. G., Gandara, D. R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ed0ff · Cited by 126
Self-citationYAP promotes erlotinib resistance in human non-small cell lung cancer cells
Hsu, P.-C., You, B., Yang, Y.-L., Zhang, W.-Q., Wang, Y.-C., Xu, Z., Dai, Y., Liu, S., Yang, C.-T., Li, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10458 · Cited by 119
Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer
Fujioka, N., Nguyen, J., Chen, C., Li, Y., Pasrija, T., Niehans, G. A., Johnson, K., Gupta, V., Kratzke, R. A., & Gupta, K. (2011) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318232b35a · Cited by 124
Yamada, T., Takeuchi, S., Nakade, J., Kita, K., Nakagawa, T., Nanjo, S., Nakamura, T., Matsumoto, K., Soda, M., Mano, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2972 · Cited by 133
Kim, J. W., Kim, H., Im, S., Kang, S., Hur, H.-S., Yoon, Y., Oh, D., Kim, J. H., Lee, D. S., Kim, T., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.07.018 · Cited by 119
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J., Barretina, J., & Tabernero, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 117
Lai, G. G. Y., Lim, T. H., Lim, J., Liew, P. J. R., Kwang, X. L., Nahar, R., Aung, Z. W., Takano, A., Lee, Y. Y., Lau, D. P. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00177 · Cited by 118
Algae-Derived Bioactive Compounds with Anti-Lung Cancer Potential
Saadaoui, I., Rasheed, R., Abdulrahman, N., Bounnit, T., Cherif, M., Al Jabri, H., & Mraiche, F. (2020) · Marine Drugs · doi:10.3390/md18040197 · Cited by 118
Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers
Yu, J., Fang, T., Yun, C., Liu, X., & Cai, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.847835 · Cited by 133
de Miguel, F. J., Gentile, C., Feng, W. W., Silva, S. J., Sankar, A., Expósito, F., Cai, W. L., Melnick, M. A., Robles-Oteíza, C., Hinkley, M. M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.005 · Cited by 128
Self-citationCho, J., Chen, L., Sangji, N., Okabe, T., Yonesaka, K., Francis, J. M., Flavin, R. J., Johnson, W., Kwon, J., Yu, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1145 · Cited by 117
“In many ways, this is reminiscent of gefitinib sensitivity, for which there are cells and tumors with gefitinib-sensitive EGFR mutations that are nevertheless resistant to the drug, due to additional genomic events such as the T790M mutation (10, 11), PTEN deletion (50), andMET amplification (51).”
BackgroundSelf-citationDirectly targeting transcriptional dysregulation in cancer
Gonda, T. J., & Ramsay, R. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4018 · Cited by 124
Molecular Pathology of Non–Small Cell Lung Cancer: A Practical Guide
Aisner, D. L., & Marshall, C. B. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpfr12wjkceezz · Cited by 145
Predictive approaches for drug combination discovery in cancer
Madani Tonekaboni, S. A., Soltan Ghoraie, L., Manem, V. S. K., & Haibe-Kains, B. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbw104 · Cited by 115
The RTK Interactome: Overview and Perspective on RTK Heterointeractions
Paul, M. D., & Hristova, K. A. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00467 · Cited by 127
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 131
Thirty Years of HER3: From Basic Biology to Therapeutic Interventions
Haikala, H. M., & Jänne, P. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4465 · Cited by 115
Self-citationAlteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
Shen, H., Zhu, F., Liu, J., Xu, T., Pei, D., Wang, R., Qian, Y., Li, Q., Wang, L., Shi, Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103305 · Cited by 123
The role of the c-Met pathway in lung cancer and the potential for targeted therapy
Sattler, M., Hasina, R., Reddy, M. M., Gangadhar, T., & Salgia, R. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011408636 · Cited by 115
Komurov, K., Tseng, J., Muller, M., Seviour, E. G., Moss, T. J., Yang, L., Nagrath, D., & Ram, P. T. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.25 · Cited by 116
Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Meric‐Bernstam, F., Frampton, G. M., Ferrer-Lozano, J., Yelensky, R., Fidalgo, J. A. P., Wang, Y., Palmer, G. A., Ross, J. S., Miller, V. A., Su, X., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0482 · Cited by 129
Huang, F., Hurlburt, W. W., Greer, A. L., Reeves, K. A., Hillerman, S. M., Han, C. L., Fargnoli, J., Finckenstein, F. G., Gottardis, M. M., & Carboni, J. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0391 · Cited by 114
The Dark Side of Cell Signaling: Positive Roles for Negative Regulators
Lemmon, M. A., Freed, D. M., Schlessinger, J., & Kiyatkin, A. (2016) · Cell · doi:10.1016/j.cell.2016.02.047 · Cited by 115
The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer
Suresh, R., Ali, S. S., Ahmad, A., Philip, P. A., & Sarkar, F. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_4 · Cited by 122
Wang, R., Yamada, T., Kita, K., Taniguchi, H., Arai, S., Fukuda, K., Terashima, M., Ishimura, A., Nishiyama, A., Tanimoto, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18442-4 · Cited by 115
Camidge, D. R., Barlési, F., Goldman, J. W., Morgensztern, D., Heist, R. S., Vokes, E. E., Spira, A. I., Angevin, E., Su, W., Hong, D. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00739 · Cited by 127
CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Bao, R., Lai, C.-J., Qu, H., Wang, D.-G., Yin, L., Zifcak, B. M., Atoyan, R., Wang, J., Samson, M., Forrester, J. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0152 · Cited by 116
Milligan, S. A., Burke, P., Coleman, D. T., Bigelow, R. L. H., Steffan, J. J., Carroll, J. L., Williams, B. J., & Cardelli, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0109 · Cited by 119
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Rothschild, S. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 115
HGF-independent potentiation of EGFR action by c-Met
Dulak, A. M., Gubish, C. T., Stabile, L. P., Henry, C., & Siegfried, J. M. (2011) · Oncogene · doi:10.1038/onc.2011.84 · Cited by 115
Sholl, L. M., Xiao, Y., Joshi, V., Yeap, B. Y., Cioffredi, L.-A., Jackman, D. M., Lee, C., Jänne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 115
Self-citationHGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
Gusenbauer, S., Vlaicu, P., & Ullrich, A. (2012) · Oncogene · doi:10.1038/onc.2012.396 · Cited by 128
Bistrović, A., Krstulović, L., Harej, A., Grbčić, P., Sedić, M., Koštrun, S., Pavelić, S. K., Bajić, M., & Raić‐Malić, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.061 · Cited by 118
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
Huang, S., van Duijnhoven, S. M. J., Sijts, A. J. A. M., & van Elsas, A. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03404-6 · Cited by 127
Impact of EGFR mutation analysis in non-small cell lung cancer
Yamamoto, H., Toyooka, S., & Mitsudomi, T. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.021 · Cited by 125
Self-citationSmyth, E. C., Sclafani, F., & Cunningham, D. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s44941 · Cited by 120
Signaling cross-talk in the resistance to HER family receptor targeted therapy
Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 129
Wang, Y.-S., Wang, Y., Xia, H., Zhou, S., Schmid‐Bindert, G., & Zhou, C. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.1.255 · Cited by 124
C-MET inhibitors for advanced non-small cell lung cancer
Pasquini, G., & Giaccone, G. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1462336 · Cited by 119
Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer
Mukohara, T. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2010.01711.x · Cited by 114
Gadgeel, S. M., & Wozniak, A. J. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.12.001 · Cited by 121
Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
Little, A. S., Smith, P. D., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.160 · Cited by 119
Perkins, G., Lu, H., Garlan, F., & Taly, V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.10.001 · Cited by 132
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 127
The role of MET in chemotherapy resistance
Wood, G. E., Hockings, H., Hilton, D. M., & Kermorgant, S. (2021) · Oncogene · doi:10.1038/s41388-020-01577-5 · Cited by 127
Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2
Acunzo, M., Romano, G., Palmieri, D., Laganà, A., Garofalo, M., Balatti, V., Drusco, A., Chiariello, M., Nana-Sinkam, P. S., & Croce, C. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302107110 · Cited by 120
The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer
Cardarella, S., Ortiz, T. M., Joshi, V. A., Butaney, M., Jackman, D. M., Kwiatkowski, D. J., Yeap, B. Y., Jänne, P. A., Lindeman, N. I., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745bcb · Cited by 112
Self-citationEGFR mutations and the terminal respiratory unit
Yatabe, Y. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9205-8 · Cited by 118
Mueller, K. L., Madden, J. M., Zoratti, G. L., Kuperwasser, C., List, K., & Boerner, J. L. (2012) · Breast Cancer Research · doi:10.1186/bcr3224 · Cited by 111
Albert, S., Arndt, C., Feldmann, A., Bergmann, R., Bachmann, D., Koristka, S., Ludwig, F., Ziller-Walter, P., Kegler, A., Gärtner, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1287246 · Cited by 116
Gao, J., Li, H.-R., Jin, C., Jiang, J., & Ding, J. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02075-1 · Cited by 124
Alam, M., Alam, S., Shamsi, A., Adnan, M., Elasbali, A. M., Al‐Soud, W. A., Alreshidi, M. M., Hawsawi, Y. M., Tippana, A., Pasupuleti, V. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869672 · Cited by 137
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer
Graveel, C. R., DeGroot, J. D., Su, Y., Koeman, J., Dykema, K., Leung, S., Snider, J., Davies, S. R., Swiatek, P. J., Cottingham, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810403106 · Cited by 112
Liu, L., Zeng, W., Wortinger, M. A., Yan, S., Cornwell, P. D., Peek, V. L., Stephens, J. R., Tetreault, J. W., Xia, J., Manro, J. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0543 · Cited by 111
Autophagic pathways as new targets for cancer drug development
Liu, B., Cheng, Y., Liu, Q., Bao, J.-K., & Yang, J.-M. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.118 · Cited by 110
Montero, J. C., Barrueco, R. R., Ocaña, A., Díaz-Rodríguez, E., Esparís-Ogando, A., & Pandiella, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5133 · Cited by 128
Van Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2752 · Cited by 110
Kim, H.-P., Han, S.-W., Song, S., Jeong, E.-G., Lee, M.-Y., Hwang, D., Im, S., Bang, Y.-J., & Kim, T.-Y. (2013) · Oncogene · doi:10.1038/onc.2013.285 · Cited by 121
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
Park, K.-S., Raffeld, M., Moon, Y. W., Xi, L., Bianco, C., Pham, T., Lee, L. C., Mitsudomi, T., Yatabe, Y., Okamoto, I., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73048 · Cited by 110
Self-citationDr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer
Pavelka, N., Rancati, G., & Li, R. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.06.003 · Cited by 110
Dong, J., Li, B., Lin, D. C.-C., Zhou, Q., & Huang, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00230 · Cited by 123
Heat shock protein 90: biological functions, diseases, and therapeutic targets
Wei, H., Zhang, Y., Jia, Y., Chen, X., Niu, T., Chatterjee, A., He, P., & Hou, G. (2024) · MedComm · doi:10.1002/mco2.470 · Cited by 131
Targeting EGFR in Lung Cancer: Current Standards and Developments
Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108
Progressive 3q Amplification Consistently Targets SOX2 in Preinvasive Squamous Lung Cancer
McCaughan, F. M., Pole, J. C. M., Bankier, A. T., Konfortov, B. A., Carroll, B., Falzon, M., Rabbitts, T. H., George, P. J., Dear, P. H., & Rabbitts, P. H. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0005oc · Cited by 109
Jakobsen, K. R., Demuth, C., Sorensen, B. S., & Nielsen, A. L. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.04.07 · Cited by 106
Huang, W.-C., Jang, T., Tung, S.-L., Yen, T., Chan, S., & Wang, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1091-5 · Cited by 116
Written on behalf of AME Lung Cancer Collaborative Group, Song, Y., Hu, C., Xie, Z., Wu, L., Zhu, Z., Rao, C., Liu, L., Chen, Y., Liang, N., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.17 · Cited by 113
Self-citationNoronha, A., Nataraj, N. B., Lee, J. S., Zhitomirsky, B., Oren, Y., Oster, S. K., Lindzen, M., Mukherjee, S., Will, R. D., Ghosh, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0111 · Cited by 117
Yanagita, M., Redig, A. J., Paweletz, C. P., Dahlberg, S. E., O'Connell, A., Feeney, N., Taibi, M., Boucher, D., Oxnard, G. R., Johnson, B. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0909 · Cited by 108
Self-citationErlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients
Plotkin, S. R., Halpin, C. F., McKenna, M. J., Loeffler, J. S., Batchelor, T. T., & Barker, F. G. (2010) · Otology & Neurotology · doi:10.1097/mao.0b013e3181eb328a · Cited by 114
SYNTHESIS: Cancer research meets evolutionary biology
Pepper, J. W., Scott Findlay, C., Kassen, R., Spencer, S. L., & Maley, C. C. (2009) · Evolutionary Applications · doi:10.1111/j.1752-4571.2008.00063.x · Cited by 109
Chen, H.-J., Mok, T. S. K., Chen, Z. H., Guo, A., Zhang, X., Su, J., & Wu, Y.-L. L. C. (2009) · Pathology & Oncology Research · doi:10.1007/s12253-009-9167-8 · Cited by 107
Self-citationSpheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation
Endo, H., Okami, J., Okuyama, H., Kumagai, T., Uchida, J., Kondo, J., Takehara, T., Nishizawa, Y., Imamura, F., Higashiyama, M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779ccf · Cited by 118
Regulation of ERBB3/HER3 signaling in cancer
Mujoo, K., Choi, B.-K., Huang, Z., Zhang, N., & An, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2655 · Cited by 114
Harbinski, F., Craig, V. J., Sanghavi, S., Jeffery, D., Liu, L., Sheppard, K. A., Wagner, S., Stamm, C., Buness, A., Chatenay-Rivauday, C., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0237 · Cited by 107
Targeting MET Amplification as a New Oncogenic Driver
Kawakami, H., Okamoto, I., Okamoto, W., Tanizaki, J., Nakagawa, K., & Nishio, K. (2014) · Cancers · doi:10.3390/cancers6031540 · Cited by 118
Yoshida, T., Zhang, G., Smith, M. A., Lopez, A. S., Bai, Y., Li, J., Fang, B., Koomen, J., Rawal, B., Fisher, K. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1559 · Cited by 107
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.007 · Cited by 106
Mechanisms of tumor resistance to EGFR-targeted therapies
Hopper-Borge, E. A., Nasto, R. E., Ratushny, V., Weiner, L. M., Golemis, E. A., & Astsaturov, I. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712590902735795 · Cited by 119
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
Lin, L., Asthana, S., Chan, E., Bandyopadhyay, S., Martins, M. M., Olivas, V., Yan, J. J., Pham, L., Wang, M. M., Bollag, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320956111 · Cited by 105
Azuma, K., Kawahara, A., Sonoda, K., Nakashima, K., Tashiro, K., Watari, K., Izumi, H., Kage, M., Kuwano, M., Ono, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1866 · Cited by 106
Donev, I. S., Wang, W., Yamada, T., Li, Q., Takeuchi, S., Matsumoto, K., Yamori, T., Nishioka, Y., Sone, S., & Yano, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1993 · Cited by 119
Nakagawa, T., Tohyama, O., Yamaguchi, A., Matsushima, T., Takahashi, K., Funasaka, S., Shirotori, S., Asada, M., & Obaishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01343.x · Cited by 106
Suzuki, S., Yonesaka, K., Teramura, T., Takehara, T., Kato, R., Sakai, H., Haratani, K., Tanizaki, J., Kawakami, H., Hayashi, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0856 · Cited by 105
“Alternatively, human epidermal growth factor receptor 3 (HER3)/MET coupling may induce HER3-mediated PI3K–AKT signaling, as observed in EGFR-mutated NSCLC (23).”
BackgroundMethodVivanco, I., Rohle, D., Versele, M., Iwanami, A., Kuga, D., Oldrini, B., Tanaka, K., Dang, J., Kubek, S., Palaskas, N., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911188107 · Cited by 105
Use of molecular markers for predicting therapy response in cancer patients
Duffy, M. J., O’Donovan, N., & Crown, J. P. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.004 · Cited by 123
Piñeiro-Yáñez, E., Reboiro‐Jato, M., Goméz-López, G., Perales-Patón, J., Troulé, K., Rodríguez, J. M., Tejero, H., Shimamura, T., Lopez-Casas, P. P., Carretero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0546-1 · Cited by 123
Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
Halliday, P. R., Blakely, C. M., & Bivona, T. G. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0770-x · Cited by 115
Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer
VanMeter, A. J., Rodriguez, A. S., Bowman, E. D., Jen, J., Harris, C. C., Deng, J., Calvert, V. S., Silvestri, A., Fredolini, C., Chandhoke, V., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800204-mcp200 · Cited by 105
Nishie, K., Kawaguchi, T., Tamiya, A., Mimori, T., Takeuchi, N., Matsuda, Y., Omachi, N., Asami, K., Okishio, K., Atagi, S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826913f7 · Cited by 107
Xu, L., Kikuchi, E., Xu, C., Ebi, H., Ercan, D., Cheng, K. A., Padera, R. F., Engelman, J. A., Janne, P. A., Shapiro, G. I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3720 · Cited by 117
Self-citationActivation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
Corso, S., Ghiso, E., Cepero, V., Sierra, J. R., Migliore, C., Bertotti, A., Trusolino, L., Comoglio, P. M., & Giordano, S. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-121 · Cited by 104
Lung cancer in never smokers: Change of a mindset in the molecular era
Lee, Y. J., Kim, J.-H., Kim, S. I., Ha, S., Mok, T. S. K., Mitsudomi, T., & Cho, B. C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.013 · Cited by 115
Self-citationChen, H., Kuo, T., Tseng, C., Ma, J., Yang, S., Yen, C., Yang, C., Sung, S., & Su, J. (2016) · Hepatology · doi:10.1002/hep.28773 · Cited by 104
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
The role of miR-130a in cancer
Zhang, H.-D., Jiang, L., Sun, D., Li, J., & Ji, Z. (2017) · Breast Cancer · doi:10.1007/s12282-017-0776-x · Cited by 110
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
Ghiso, E., Migliore, C., Ciciriello, V., Morando, E., Petrelli, A., Corso, S., De Luca, E., Gatti, G., Volante, M., & Giordano, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.003 · Cited by 103
Metadata
- Authors
- Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., & Jänne, P. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
- ORCID
- Venue
- Science
- Published
- 2007-05-18
- Volume
- 316
- Issue
- 5827
- Pages
- 1039-1043
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1998971866
- Cited by
- 4,496
- References
- 22
- Citations by year
- 2026: 97 · 2025: 109 · 2024: 123 · 2023: 136 · 2022: 152 · 2021: 191 · 2020: 182 · 2019: 214 · 2018: 269 · 2017: 288 · 2016: 291 · 2015: 375 · 2014: 349 · 2013: 369 · 2012: 345
- FWCI
- 207.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca111560-05)
- National Cancer Institute (R01-CA111560, P01CA089021, R01CA114465, P20CA090578, P20 CA 90578-02, 1K12CA87723-01, K08CA120060, K12CA087723)
- National Institute of General Medical Sciences (GM 41890, R01GM041890)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- MET amplification, gefitinib resistance, lung cancer, HER3, PI3K signaling, EGFR kinase inhibitors, erlotinib, drug resistance, ErbB receptors, MET oncogene
- MeSH terms
- Gefitinib, Proto-Oncogene Mas, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cricetulus, Enzyme Inhibitors, Gene Amplification, Cricetinae, Humans, Indoles, Lung Neoplasms, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Sulfones, Signal Transduction, CHO Cells, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Receptor, ErbB-3, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.